Coventry, UK (25 March 2024): Medherant Limited (“Medherant”) announces that it has entered into a Development Collaboration Agreement with Bayer for the development of a transdermal patch product for delivery of an already-approved oral medicine.

For the last 3 years, Medherant and Bayer have worked on formulation development for this product, utilising Medherant’s expertise in the use of laboratory models for assessment of transdermal drug delivery with the TEPI Patch® technology.

The Development and Collaboration Agreement marks the movement of the collaboration to the next phase of development as Medherant and Bayer move the programme to non-clinical studies and approach technology transfer for patch production at Medherant’s contract manufacturing partner. Medherant is responsible for leading the programme through to completion of the clinical proof of concept study.

Following a successful outcome to the clinical proof of concept study, Medherant and Bayer expect to negotiate a definitive licence agreement to enable Bayer to complete the development programme and pursue commercialisation of this novel TEPI Patch transdermal drug delivery product. Medherant anticipates that the licence agreement will provide for payments to Medherant through the development and registration process as well as royalties payable on sales of this product.

Bayer is committed to transforming self-care by offering precision health solutions to enable consumers to better understand and make informed decisions about their own personal health and lifestyle choices.

About Medherant

Medherant’s lead development product is a testosterone patch for post-menopausal women utilising Medherant’s novel transdermal TEPI Patch proprietary technology. Despite the recommendation contained in the NICE Menopause Guidelines and Global Consensus Position Statement on the Use of Testosterone Therapy for Women there is no approved testosterone product for women in the UK, EU or USA.

The company was founded by University of Warwick’s Professor of Polymer Chemistry, Professor David Haddleton and is developing the novel transdermal TEPI Patch technology which can create patches that have more favourable wear characteristics for patients, with good adhesion and are non-irritant to patients whilst not leaving adhesive residue on patients’ skin.

In addition to developing its own products, Medherant collaborates with pharmaceutical companies in developing transdermal patch products for already approved drugs.

TEPI Patch is a registered trademark of Medherant Limited.

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros.